• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Chemed Corp

    5/20/25 10:21:08 AM ET
    $CHE
    Medical/Nursing Services
    Health Care
    Get the next $CHE alert in real time by email
    S-8 1 che-20250520xs8.htm FORM S-8 20250519S8

       

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

    

    

    CHEMED CORPORATION

    (Exact name of registrant as specified in its charter)

    

    

     

     

    Delaware

     

    31-0791746

    (State or other jurisdiction of incorporation or organization)

     

    (IRS Employer Identification No.)

    255 E. Fifth Street,  Suite 2600,  Cincinnati,  Ohio

     

    45202

    (Address of principal executive offices)

     

    (Zip code)

    

    2025 STOCK INCENTIVE PLAN

    (Full title of the plan)

     

    Brian C. Judkins

    255 E. Fifth Street, Suite 2600

    Cincinnati, Ohio 45202

    (Name and address of agent for service)

     

    (513)  762-6690

    (Telephone number, including area code, of agent for service)

    

    

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

    

    

     

     

     

     

     

     

     

     

     

     

    Large Accelerated Filer

    ☒

     

    Accelerated Filer

    ☐

     

    Non-accelerated Filer

    ☐

     

    Smaller Reporting Company

    ☐

    

    Emerging growth company ☐

    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act  ☐

    

    

    

     

     

     

     

     


     

    EXPLANATORY NOTE

    

    The stockholders of Chemed Corporation (the “Registrant”) approved the Chemed Corporation 2025 Stock Incentive Plan (the “2025 Plan”) on May 19, 2025 (the “Effective Date”).  As provided in the 2025 Plan, 1,100,000 shares of common stock, par value $1.00 per share (“Shares”), are available for issuance thereunder.  The purpose of this registration statement is to register the Shares for future issuance under the 2025 Plan.

    


     

    PART I

    

    Item 1.  Plan Information

    

            The information required by Item 1 is included in documents sent or given to participants in the 2025 Plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

    

    

    Item 2.  Registrant Information and Employee Plan Annual Information

    

            The information required by Item 2 is included in documents sent or given to participants in the 2025 Plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

    


     

    PART II

    

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    

    Item 3.  Incorporation of Documents by Reference

    

            The following documents filed by the Registrant with the Securities and Exchange Commission are incorporated by reference in this Registration Statement.

    

    (1) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024; filed with the Commission on February 28, 2025, as subsequently amended on April 1, 2025.

    

    (2) The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on April 28, 2025;

    

    (3) The Registrant’s current reports on Form 8-K filed with the Commission on February 26, 2025 and April 23, 2025;

    

            (4) The Registrant's Proxy Statement dated April 7, 2025; and

    

    (5) The "Description of Capital Stock" incorporated by reference in the Registrant's Registration Statement on Form S-3 filed on November 26, 1991, including any amendments or reports filed to update such description.

    

    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act, as amended (the “Exchange Act”) prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the Shares offered have been sold or that deregisters all of such Shares then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of the filing of such reports and documents.  Unless expressly incorporated into this registration statement, a report furnished but not filed on Form 8-K shall not be incorporate by reference into this registration statement to the extent furnished but not filed.

    

    Item 4.  Description of Securities

    

            N/A

    

    Item 5.  Interest of Named Experts and Counsel

    

    Legal matters in connection with the issuance of the Registrant 's Capital Stock offered hereby have been passed upon by Brian C. Judkins, 255 East 5th Street, Suite 2600, Cincinnati, Ohio 45202. Mr. Judkins is Vice President, Chief Legal Officer and Secretary, and a stockholder of the Registrant, and is eligible to participate in the 2025 Plan.

    

    Item 6.  Indemnification of Directors and Officers

    

    The following summary is qualified in its entirety by reference to the complete text of any statutes referred to below, and the certificate of incorporation and the By-Laws of the Registrant. 

    

    The Certificate of Incorporation and By-laws of the Registrant, and separate Indemnity Agreements, provide for the indemnification of each director and officer of the Registrant in connection with any claim, action, suit or proceeding brought or threatened by reason of his position with the Registrant. In addition, the General Corporation Law of the State of Delaware ("Delaware Law") including sections 102(b) and 145, permits the Registrant to indemnify its directors, officers and others against judgments, fines, amounts paid in settlement and attorneys' fees resulting from various types of legal actions or proceedings if the actions of the party being indemnified meet the standards of conduct specified in the Delaware Law. The Registrant also maintains directors and officers liability insurance for the benefit of its directors and officers.

    

    Item 7.  Exemption from Registration Claimed

            N/A


     

    Item 8.  Exhibits.

    

    

    Page Number or

    Incorporation

                          Numberby Reference

                          Under Item 601                                          File Number and

    Exhibit           Regulation                                                        Filing Date

    Number          S-K                                                 

    

    

    4.1                (4)            Certificate of Incorporation        Form S-3

                                                                           Reg. No. 33-44177

                                                                           11/26/91

    

    4.2                (4)            Amendment to Certificate of Incorporation        Form S-8 

                                       Reg. No. 333-109104

                                                                           09/25/03

    

    4.3                (4)            Amendment to Certificate of Incorporation          Form S-4

                                       Reg. No. 333-115668

                                                                           05/20/04

    

    4.4                (4)           Amendment to Certificate of Incorporation          Form 8-K

                                       05/16/06

    

    4.5                (4)            By-Laws                           Form 8-K

                                                                          12/09/22

    

    4.6                (4)            2025 Stock Incentive Plan          

                                                                           

    

    4.7                (4)            Form of Option Grant               

                                                                          

    

    4.8                (4)            Form of Performance Based Stock Award 

      

         

      5                (5)            Opinion and Consent of Counsel   

    

     23               (23)           Consent of Independent Registered Public          

                                         Accounting Firm

    

     24               (24)           Powers of Attorney                 

    

     107             (107)        Filing Fee Table                 

    


     

    Item 9.  Undertakings.

    

    (a)

    The undersigned Registrant hereby undertakes:

    

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

    

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement; and

    

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

    

    Provided, however, that paragraphs 1(a)(1)(i) and 1(a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    

    (a)

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    

    (b)

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under “Item 6—Indemnification of Directors and Officers,” or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    

    

    

     


     

    SIGNATURES

    

            Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, State of Ohio, on May 20, 2025.

    

                                    CHEMED CORPORATION

    

                                    By:  /s/ Michael D. Witzeman

                                            Michael D. Witzeman

                                           Executive Vice President, Controller and

                                           Chief Financial Officer

    

        Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    

    

    Signature                   Title                             Date

       

    

    /s/ Kevin J. McNamara         President and Chief Executive Officer                     May 20, 2025

    Kevin J. McNamara              (Principal Executive Officer)

    

    

    /s/ Michael D. Witzeman         Executive Vice President,                          May 20, 2025

    Michael D. Witzeman            Controller and Chief Financial Officer

       (Principal Financial Officer)

    

                      

          

    Ron DeLyons*                  Eileen P. McCarthy*               DIRECTORS

    Christopher J. Heaney*John M. Mount Jr.*

    Thomas C. Hutton*George J. Walsh III*

    Andrea R. Lindell*

    

    /s/ Brian C. Judkins                                             May 20, 2025

    Brian C. Judkins

    Vice President, Chief Legal Officer and Secretary

    

    

    *Brian C. Judkins signing his name hereto signs this document on behalf

    of each of the persons indicated above pursuant to powers of attorney duly

    executed, filed with the Securities and Exchange Commission.

    

                                          /s/ Brian C. Judkins

                                          Brian C. Judkins, Attorney-in-Fact

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

     


     

    INDEX TO EXHIBITS

    

    Page Number

    or

    Incorporation by Reference

    

     

     

     

     

                    

    Number

     

     

                    

    Under Item 601

    File Number

     

    Exhibit      

    Regulation

    and

    Previous

    Number       

    S-K

    Filing Date

    Exhibit

    4.1

    (4)

    Certificate of Incorporation

    Form S-3

    4.1

    

     

     

    Reg. No.

     

    

     

     

    33-44177

     

    

     

     

    11/26/91

     

    

     

     

     

     

    4.2

    (4)

    Amendment to Certificate of Incorporation

    From S-8

    4.1.1

    

     

     

    Reg. No.

     

    

     

     

    333-109104

     

    

     

     

    09/25/03

     

    

     

     

     

     

    4.3

    (4)

    Amendment to Certificate of Incorporation

    From S-4

    3.3

    

     

     

    Reg. No.

     

    

     

     

    333-115668

     

    

     

     

    05/20/04

     

    

     

     

     

     

    4.4

    (4)

    Amendment to Certificate of Incorporation

    From 8-K

    3.1

    

     

     

    05/16/06

     

    

     

     

     

     

    4.5

    (4)

    By-Laws

    From 8-K

    3.1

    

     

     

    12/09/22

     

    

     

     

     

     

    4.6

    (4)

    2025 Stock Incentive Plan

     

     

    

     

     

     

     

    4.7

    (4)

    Form of Option Grant

     

     

    

     

     

     

     

    4.8

    (4)

    Form of Performance Based Stock Award

     

     

    

     

     

     

     

    5

    (5)

    Opinion and Consent of Counsel

     

     

    

     

     

     

     

    23

    (23)

    Consent of Independent Registered Public Accounting Firm

     

     

    

     

     

     

     

    24

    (24)

    Power of Attorney

     

     

    

     

     

     

     

    107

    (107)

    Filling Fee Table

     

     

    

    

    

     


    Get the next $CHE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHE

    DatePrice TargetRatingAnalyst
    3/4/2022$609.00 → $579.00Outperform
    RBC Capital
    7/29/2021$604.00 → $609.00Outperform
    RBC Capital
    More analyst ratings

    $CHE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walsh George J Iii was granted 277 units of Capital Stock, increasing direct ownership by 9% to 3,323 units (SEC Form 4)

      4 - CHEMED CORP (0000019584) (Issuer)

      5/20/25 12:42:26 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Director Mount John Meredith Jr. was granted 277 units of Capital Stock, increasing direct ownership by 42% to 930 units (SEC Form 4)

      4 - CHEMED CORP (0000019584) (Issuer)

      5/20/25 12:33:04 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Director Mccarthy Eileen P was granted 277 units of Capital Stock, increasing direct ownership by 48% to 855 units (SEC Form 4)

      4 - CHEMED CORP (0000019584) (Issuer)

      5/20/25 12:28:19 PM ET
      $CHE
      Medical/Nursing Services
      Health Care

    $CHE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

      Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of nine directors at the Company's 2025 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2025. Stockholders also approved Chemed's executive compensation and the Company's 2025 Stock Incentive Plan. Dividend Declared Following the stockholders' meeting, Chemed's Board of Directors declared a quarterly cash dividend of 50 cents per share on the Company's capital stock, payable on June 17, 2025, to stockholders of record as of May 29, 2025. This represents the 216th consecutive quarterly dividend paid to stockholders in Chemed's

      5/19/25 2:53:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference

      Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at approximately 9:30 a.m. (ET) at The InterContinental New York Barclay Hotel in New York City. The audio webcast can be accessed by visiting the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours after the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of

      5/14/25 12:00:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2025

      Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:40 PM (PDT) at the Encore at the Wynn Las Vegas. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS i

      5/6/25 12:00:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care

    $CHE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CHE
    Financials

    Live finance-specific insights

    See more
    • VP and Chief Legal Officer Judkins Brian C bought $75,328 worth of Capital Stock (145 units at $519.50), increasing direct ownership by 9% to 1,678 units (SEC Form 4)

      4 - CHEMED CORP (0000019584) (Issuer)

      12/30/24 11:10:35 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

      Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of nine directors at the Company's 2025 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2025. Stockholders also approved Chemed's executive compensation and the Company's 2025 Stock Incentive Plan. Dividend Declared Following the stockholders' meeting, Chemed's Board of Directors declared a quarterly cash dividend of 50 cents per share on the Company's capital stock, payable on June 17, 2025, to stockholders of record as of May 29, 2025. This represents the 216th consecutive quarterly dividend paid to stockholders in Chemed's

      5/19/25 2:53:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Reports First-Quarter 2025 Results

      Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2025, versus the comparable prior-year period. Results for Quarter Ended March 31, 2025 Consolidated operating results: Revenue increased 9.8% to $646.9 million GAAP Diluted Earnings-per-Share (EPS) of $4.86, an increase of 14.6% Adjusted Diluted EPS of $5.63, an increase of 8.3% VITAS segment operating results: Net Patient Revenue of $407.4 million, an in

      4/23/25 4:15:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed To Report First-Quarter 2025 Earnings April 23, Related Conference Call To Be Held On April 24

      Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, April 24, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/ey8mpmti. Participants may also register via teleconference at: https:/

      4/1/25 12:00:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care

    $CHE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chemed Corp (Amendment)

      SC 13G/A - CHEMED CORP (0000019584) (Subject)

      2/13/24 5:01:01 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Chemed Corp (Amendment)

      SC 13G/A - CHEMED CORP (0000019584) (Subject)

      2/9/23 11:12:43 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Chemed Corp (Amendment)

      SC 13G/A - CHEMED CORP (0000019584) (Subject)

      2/9/22 3:33:36 PM ET
      $CHE
      Medical/Nursing Services
      Health Care

    $CHE
    Leadership Updates

    Live Leadership Updates

    See more
    • VITAS To Buy Hospice Assets of Covenant Care in Florida and Alabama

      VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation ("Chemed") (NYSE:CHE), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care ("Covenant") for an aggregate purchase price of $85 million. Covenant's hospice operations span the panhandle of Florida and Alabama, specifically including the Tallahassee, Marianna, Fort Walton Beach, Panama City, Crestview and Pensacola markets in Florida, and the Dothan and Mobile/Daphne markets in Alabama. The transaction is structured as an asset purchase and parties will seek to close the tra

      3/13/24 9:00:00 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Corporation Announces the Appointment of Michael D. Witzeman as CFO

      Chemed Corporation (NYSE:CHE) – Today Chemed Corporation's Board of Directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of David P. Williams from that role. Mr. Witzeman is currently Chemed's Vice President and Controller and serves as Chemed's principal accounting officer. He joined Chemed in 2005 following employment as Senior Manager of Assurance at Deloitte & Touche LLP. He is a licensed CPA and a BBA in Accounting from the University of Cincinnati and an MBA from The Ohio State University. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates t

      12/18/23 1:20:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Chemed Corporation Announces the Retirement of David P. Williams

      Chemed Corporation (NYSE:CHE) – After more than three decades, Executive Vice President and Chief Financial Officer David P. Williams has announced that he will retire as Chemed's Chief Financial Officer as of December 31, 2023, but Mr. Williams will continue to work with Chemed for the transition period and beyond in providing his guidance and the benefit of his expertise to the executive team and the Board of Directors. Throughout his career, David helped lead Chemed and its subsidiaries through unprecedented economic growth. "It has been a privilege to work with David as an integral part of our management team for these last three decades," said Chemed Chief Executive Officer, Kevin

      11/3/23 4:15:00 PM ET
      $CHE
      Medical/Nursing Services
      Health Care

    $CHE
    SEC Filings

    See more

    $CHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chemed Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CHEMED CORP (0000019584) (Filer)

      5/20/25 2:00:14 PM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • SEC Form S-8 filed by Chemed Corp

      S-8 - CHEMED CORP (0000019584) (Filer)

      5/20/25 10:21:08 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Chemed Corp

      10-Q - CHEMED CORP (0000019584) (Filer)

      4/28/25 9:06:58 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • RBC Capital reiterated coverage on Chemed with a new price target

      RBC Capital reiterated coverage of Chemed with a rating of Outperform and set a new price target of $579.00 from $609.00 previously

      3/4/22 8:31:07 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • RBC Capital reiterated coverage on Chemed with a new price target

      RBC Capital reiterated coverage of Chemed with a rating of Outperform and set a new price target of $609.00 from $604.00 previously

      7/29/21 10:52:58 AM ET
      $CHE
      Medical/Nursing Services
      Health Care
    • Oppenheimer reiterated coverage on Chemed with a new price target

      Oppenheimer reiterated coverage of Chemed with a rating of Outperform and set a new price target of $580.00 from $600.00 previously

      3/3/21 8:11:56 AM ET
      $CHE
      Medical/Nursing Services
      Health Care